Patents by Inventor Anil Kumar Chauhan

Anil Kumar Chauhan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY
    Publication number: 20220002703
    Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 6, 2022
    Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Anil Kumar Chauhan, Friedrich Scheiflinger, Barbara Plaimauer
  • ADAMTS13-containing compositions having thrombolytic activity
    Patent number: 11124787
    Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 21, 2021
    Assignees: Takeda Pharmaceutical Company Limited, Children's Medical Center Corporation
    Inventors: Denisa D. Wagner, Anil Kumar Chauhan, Friedrich Scheiflinger, Barbara Plaimauer
  • FcyRIIIa signaling generates Bcl6+PD1+CD4+ Tfh-like cells
    Publication number: 20210254001
    Abstract: Cosignaling by immune complexes in human CD4+ T cells triggers co-expression of low affinity Fc receptors, which upon signaling trigger Bcl6, PD1, IFN-?, IL-17A, and IL-21 expression. A small molecular chemical entity, a protein-biologics, peptide that inhibits production/expansion of these cells to obtain beneficial outcome in treating autoimmunity and viral infections. Quantitation of the cells that express Fc receptors in combination to PD1, Bcl6, IFN-?, IL17A, IL-21 for the assessment of the disease activity in autoimmunity and viral infections.
    Type: Application
    Filed: February 15, 2020
    Publication date: August 19, 2021
    Inventor: Anil Kumar Chauhan
  • Pharmaceutical Composition For Treating Obesity Induced By High Fat Diet And Non-Alcoholic Fatty Liver Disease By Using Trisodium Chlorin E6 Photosensitizer
    Publication number: 20200297847
    Abstract: Disclosed is a pharmaceutical composition for obesity inhibition for photodynamically inhibiting obesity, containing trisodium Chlorin e6 as an active ingredient.
    Type: Application
    Filed: June 9, 2020
    Publication date: September 24, 2020
    Inventors: Yong Wan KIM, Anil Kumar CHAUHAN
  • ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY
    Publication number: 20190161746
    Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
    Type: Application
    Filed: January 30, 2019
    Publication date: May 30, 2019
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Anil Kumar CHAUHAN, Friedrich SCHEIFLINGER, Barbara PLAIMAUER
  • ADAMTS13-containing compositions having thrombolytic activity
    Patent number: 10233436
    Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: March 19, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH, Children's Medical Center Corporation
    Inventors: Denisa D. Wagner, Anil Kumar Chauhan, Friedrich Scheiflinger, Barbara Plaimauer
  • USE OF MEMBRANE ATTACK COMPLEX (MAC) AND IMMUNE COMPLEXES (ICs) TO ACTIVATE T-CELLS AND THE GENERATION OF REGULATORY T CELLS
    Publication number: 20120009208
    Abstract: The invention describes the use of antigen-antibody complexes also known in the field as immune complexes to activate T cells and their potential to differentiate them into effector T cells for use in therapy. It also describes a process to achieve benefit from disrupting this T cell activation mediated by antigen-antibody complex and sublytic MAC of the complement system.
    Type: Application
    Filed: July 4, 2011
    Publication date: January 12, 2012
    Inventor: Anil Kumar Chauhan